22:48 , Mar 9, 2017 |  BC Innovations  |  Finance

Pharmas learn their A, B, seeds

Having stepped in to fill the venture funding void after the financial crisis, corporate VCs are emerging as financing engines for new company formation. Driven largely by the flood of interest in immuno-oncology, pharmas are...
07:00 , Sep 29, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD163

Neurology INDICATION: Parkinson's disease (PD) Rat studies suggest CD163-targeting liposomes loaded with anti-inflammatory agents could help treat PD. In a rat model of PD, numbers of striatum-infiltrating CD163-positive macrophages were higher than in normal rats. In the...
08:00 , Jan 6, 2011 |  BC Innovations  |  Strategy

LU Bio: Swedish hybrid

Lund University Bioscience AB is not a typical investment company or VC. As a kind of hybrid between a company, an incubator and a VC, LU Bio seeks out technology with commercial potential from academic...
07:00 , Apr 24, 2006 |  BC Week In Review  |  Clinical News

CRx-170: Phase IIa data

In a single-blind, U.K. Phase IIa study in 19 patients, one week dosing of CRx-170 missed the primary endpoint of change in circulating monocyte CD163, an inflammatory marker. The compound met the secondary endpoint by...
07:00 , Apr 24, 2006 |  BioCentury  |  Product Development

Secondary success

CombinatoRx Inc.'s CRx-170 missed the primary endpoint in a Phase IIa trial in asthma last week, but the company is encouraged by the fact that the low dose combination of budesonide and nortriptyline met a...
01:38 , Apr 19, 2006 |  BC Extra  |  Clinical News

CombinatoRx's CRx-170 misses endpoint

CRXX's CRx-170 missed the primary endpoint of change in circulating monocyte CD163 in a Phase II trial to treat asthma. The compound met the secondary endpoint of FEV1, with a 6% improvement from baseline (p=0.045)....